Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab). (2016)
Attributed to:
Evaluating, adapting and extending individual patient data (IPD) methods of evidence synthesis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/ijc.30280
PubMed Identifier: 27450994
Publication URI: http://europepmc.org/abstract/MED/27450994
Type: Journal Article/Review
Volume: 139
Parent Publication: International journal of cancer
Issue: 10
ISSN: 0020-7136